Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may pinpoint cause of stunted fetal growth

NCT ID NCT05151289

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study is testing whether a simple blood test can help doctors tell apart two main causes of intrauterine growth restriction (IUGR) — a condition where a baby grows slower than expected in the womb. The test measures the ratio of two proteins, sFlt-1 and PlGF, which are linked to blood vessel problems in the placenta. Researchers will compare the test results with placental tissue analysis after birth to see if the test can accurately identify vascular causes. The study involves 167 pregnant women with a diagnosis of IUGR, and the findings could lead to a non-invasive way to guide pregnancy management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood test measuring the sFlt-1/PlGF ratio
What this could lead to
If this blood test works, it could help doctors identify the cause of fetal growth restriction without invasive procedures, leading to better monitoring and care for at-risk pregnancies.
What could go wrong
This is a diagnostic study, not a treatment trial. The test may not be accurate enough to replace current methods, and results may vary across different populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

167 people

The number who actually took part.

Started

Jan 2020

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \> 18 years old * Singleton pregnancy * Date of conception evaluated by ultrasound \< 14 WG * Consulting in one of the 3 participating centers for IUGR * Estimated fetal weight \< 5th centile (according to Hadlock 3 et CFEF) * Between 22+0 WG et 34+6 WG Exclusion Criteria: * Major birth defect diagnosed at time of inclusion * Abnormality of caryotype known at time of inclusion * Confirmed preeclampsia at time of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fetal growth restriction (FGR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fetal growth restriction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fetal growth restriction (FGR) Intrauterine growth restriction

Contacts and locations

Locations

  • Hôpital Louis Mourier

    Colombes, 92700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.